Nasal vaccine or monoclonal therapy: Which is winning weapon against SARS-CoV-2 variants in 2022?

Detalles Bibliográficos
Autores principales: Lo Muzio, Lorenzo, Spirito, Francesca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Society of Global Health 2022
Materias:
Viewpoints
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107288/
https://www.ncbi.nlm.nih.gov/pubmed/35567581
http://dx.doi.org/10.7189/jogh.12.03023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107288/
https://www.ncbi.nlm.nih.gov/pubmed/35567581
http://dx.doi.org/10.7189/jogh.12.03023

Ejemplares similares